1 rich Libsyn https://www.libsyn.com 300 600 🧬 Could a single infusion replace decades of lipid-lowering therapy? &amp;nbsp; The new NEJM study on VERVE-102 explores in vivo base editing of PCSK9 using CRISPR-inspired adenine base editing technology. In this phase 1 trial, a one-time infusion produced LDL cholesterol reductions up to 62% with durable effects extending beyond 1 year. ❤️ &amp;nbsp; This may represent a major shift from chronic pharmacotherapy toward “once-and-done” genomic cardiovascular prevention. &amp;nbsp; The science, safety, clinical implications, and future of gene-editing cardiology on “Dr RR Baliga’s Podkast for the Kurious Doc.” 🎙️🧠 &amp;nbsp; #Cardiology #CRISPR #PCSK9 #PrecisionMedicine #Genomics #LDL #NEJM #MedicalInnovation #PreventiveCardiology #medicalpodca Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity! http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/41435030/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/202335035